An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials.
about
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitorsSafety of dipeptidyl peptidase 4 inhibitors: a perspective reviewSafety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus.Optimal therapy of type 2 diabetes: a controversial challengeRandomized controlled clinical trial of a combination therapy of vildagliptin plus an α-glucosidase inhibitor for patients with type II diabetes mellitus.Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular dataEmerging gliptins for type 2 diabetes.Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE)Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data.Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease.Management of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guidelines.Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE studyComparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial.Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitusEfficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study.Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin.An inhibitory antibody against dipeptidyl peptidase IV improves glucose tolerance in vivoManaging diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptinExperience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment.One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus.Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment.Add-on therapies to metformin for type 2 diabetes.Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.A review of gliptins in 2011.Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists.Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks.Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
P2860
Q26778608-35F2444B-2917-490E-AC3C-1D4E34CB723EQ26863262-92BF33CD-C24D-4D2E-8905-6B3FF8D46C5AQ33412360-0C3C2766-D2AC-4DC2-8449-C2C01D856206Q33577712-59B19B45-024D-4EE3-A1A7-2963E9E36215Q33706160-6B84AA9F-2DBB-441F-85BD-D5BAE3AC5738Q34128612-25A8B7D9-A61E-4313-9A2F-AF108112C64FQ34347884-3A7287B1-44DF-4F41-8D76-8C5C1575E8EEQ34507122-0CAD800F-06AD-49DC-84B8-CCDFCB2A3EF5Q34507149-75975F7B-411A-468E-90BE-05B0ADC2AB8EQ34726395-9638F90E-DEA1-4F16-B68F-92F636606916Q34783302-33D39B31-4D3E-41C1-90F9-A52CD570084BQ35073384-228C20A7-74C0-4555-875C-5BAF273BFCB1Q35142675-91F14842-F624-4D03-8852-C1F0C1292628Q35921498-F57B682F-317D-4081-877F-825A081F35DFQ35997324-419C9DAC-5C69-4E2B-823E-B6B0E7EAAE08Q36365793-73D49F72-6BE2-48C0-A854-BEAFA9D157FEQ36428052-7B9AD380-1645-403B-91E9-9D323A8CF7D4Q36526318-8227A230-7CF6-4518-B348-E61A83736234Q36805122-4E40740B-306E-4BC2-81EF-B98BBE56D707Q37468480-46697E64-5A48-4BD2-9775-CE21AE745824Q37476451-1E4139A8-EB29-4464-BFF6-03900DC05EF1Q37652091-E84309B0-0AC6-4B45-BBCB-F87306AEF5B2Q37721962-6DFDD3C6-620D-4FB6-9654-3A442243592EQ37818234-EE7372BE-F580-4942-B6FF-1C9106A303A9Q37837059-9EB41B92-2C4D-4B07-9F84-081C98A0C110Q37900151-DBB1BF64-2C08-4F41-BD6D-AB70C0FBE172Q37900690-8E59AA0D-C989-4EB4-A44F-EB8F20F3644BQ37910902-B68FBFDF-B2BC-4E9D-BB81-1C297C3B2A6CQ37965612-27554A12-B29E-4269-B393-5543434EEC3DQ37991385-C6B1956B-5B64-4ACD-B237-E1F82D41BE53Q37992956-8B6138B2-9A54-4B33-B34B-9EE21B57A5B4Q38004088-98D0A889-B757-4BA6-853F-B99926E04083Q38012068-50B90DE6-9B5B-4965-BF8D-BCDA66250479Q38017726-FA70F8BC-B2A5-4E1C-BF72-3FDA041CDD99Q38083641-C31F166B-902B-4883-B032-FDF88005A718Q38086611-3EC6BD6F-2860-4460-9E8B-99CD1C63C670Q38088195-916CC9E7-D9DB-49DE-9F6D-FFE1F8AE2274Q38101993-3D1F9BA6-D2F4-4900-8907-39138E5DC42BQ38104338-3BF79E4A-D96F-43D3-94A1-109032B7F4A3Q38107347-487AEF9D-ACFC-4204-81BF-068B9E795318
P2860
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
An assessment of adverse effec ...... se II and III clinical trials.
@en
An assessment of adverse effec ...... se II and III clinical trials.
@nl
type
label
An assessment of adverse effec ...... se II and III clinical trials.
@en
An assessment of adverse effec ...... se II and III clinical trials.
@nl
prefLabel
An assessment of adverse effec ...... se II and III clinical trials.
@en
An assessment of adverse effec ...... se II and III clinical trials.
@nl
P2093
P921
P1476
An assessment of adverse effec ...... se II and III clinical trials.
@en
P2093
A Couturier
A Schweizer
M Ligueros-Saylan
P2860
P304
P356
10.1111/J.1463-1326.2010.01214.X
P577
2010-06-01T00:00:00Z